74 results about "Maternal antibody" patented technology

The invention discloses a method for segregated early weaning of piglets, which comprises the steps of medicine adding, segregation, early transfer and the feeding of early weaning by piglet feed, wherein the medicine adding is performed before and after the delivery of a sow, the advanced medicine adding is used to kill off microorganisms which is expected to be killed, and the medicine adding is also performed from the birth of a suckling piglet to the weaning; the segregation adopts that the parturient sow is transferred into a clean farrowing house for delivery from the pregnancy, and the piglet at the age of between 10 and 14 days is transferred into a clean and comfortable breeding house from the farrowing house; when the level of a maternal antibody of the piglet at the age of between 10 and 14 days is in higher state, the piglet is moved away from the sow and is transferred into a cleaner environment; and the piglet feed for segregated early weaning adopts four stages to feed. The piglet has early weaning segregation time, high survival rate, and quick growth speed, the segregated early weaning of the piglet can save feeding cost of the sow, improve the yearly parity number of the sow, improve the utilization rate of the farrowing house, and reduce the probability that the piglet is infected with sow diseases, and a segregated early weaning technology of the piglet is suitable for the application of modern pig farms.

The present invention discloses a strain of a recombinant cell line for stably expressing classical swine fever virus E2 protein, and applications of the recombinant cell line in preparation of subunit vaccines and diagnosis reagents of classical swine fever, wherein specifically the recombinant cell line is BCSFV-E2, is preserved in the China General Microbiological Culture Collection Center, and has the preservation number of CGMCC No.7719. The classical swine fever subunit vaccine prepared by using the recombinant cell line has characteristics of high safety, good immunization effect, easy mass production, less being susceptible to exogenous virus pollution or influence of antibodies, and no influence of the maternal antibody on immunization of swine, and can induce and produce high level classical swine fever virus neutralization antibodies after the swine is immunized. In addition, the present invention further discloses a method for constructing the recombinant mammalian cell line, a method for preparing the classical swine fever subunit vaccine, and applications of the antigen expressed by the recombinant cell line in preparation of classical swine fever prevention vaccines and diagnosis reagents.

The invention provides goose parvovirus (GPV) and applications thereof, and belongs to the technical field of biology. The invention provides a goose parvovirus GPV-YZ strain as well as applications thereof in preparing medicaments for preventing and treating the gosling plague disease. The microorganism preservation number is CGMCC NO.8160. The invention also provides a gosling plague disease viral vaccine as well as an anti-gosling plague yolk antibody. The goose parvovirus YZ strain provided by the invention has favorable immunogenicity for the present epidemic goose parvovirus, can resist toxicity attacking of the GPV-AV240 strain, the GPV-GD strain as well as the toxic strain of the goose parvovirus, and has the protection capability against the GPV-AV240 strain and the GPV-GD strain. After breeding geese are immunized by the gosling plague disease viral vaccine provided by the invention, young geese can be protected by maternal antibodies, and can be prevented from being infected by gosling plague viruses. The anti-gosling plague yolk antibody provided by the invention can prevent and treat gosling disease.

The present invention provides methods for identifying and/or enriching fetal cells from maternal blood, using as fetal cell markers the antibodies that the mother produces against paternally inherited fetal antigens. The fetal cell-maternal antibody complexes are identified and isolated using labelled agents that bind to the maternal antibodies. The present invention also provides fetal cells, isolated by use of said maternal antibodies, as a source of fetal DNA for prenatal genetic diagnosis of the fetus.

The invention discloses a novel duck reovirus strain NDRV-JM85 with a preservation number of CCTCC NO: V201127. The novel duck reovirus strain NDRV-JM85 is used as a virus seed to inoculate an allantoic cavity of a muscovy duck embryo and obtain a virus-containing allantoic fluid, or inoculate an MDEF cell to obtain cytotoxin when a CPE reaches 75%. The virus liquid is inactivated by formaldehyde and added with a white oil adjuvant, and the mixture is mixed thoroughly to from a safe and effective oil emulsion inactivated vaccine for novel duck reovirus. The vaccine is used to immunize a laying hen three times, with an immunization interval of 21 days and 1.0 ml for each hen at each time. Eggs laid 21-63 days after the three immunizations are gained, and extracted yolk and a proper amount of disinfected normal saline is prepared into a hyperimmune antibody preparation for the novel duck reovirus. A duckling without an NDRV maternal antibody is injected with the antibody preparation at 1-2 days old for 0.5ml / duckling, or a duckling with a maternal antibody is injected with the antibody preparation at 10 days old for 1.0 ml / duckling, so as to prevent and control the novel duck reovirus. The invention applies to large-scale production under a GMP condition.

The present invention relates to CpG DNA, and is especially specific chicken CpG ODN and its use as the H5-subtype bird flu DNA vaccine adjuvant. The CpG ODN sequence is 5í»-TTGGAACGTTCCTTTCCAACGTTGGTTTGGAACGTTCCTT-3í». The H5-subtype bird flu DNA vaccine with the CpG ODN adjuvant is taken by chicken through oral taking or nose dropping to immunize, and can raise the protection rate against the challenge virus and the intestinal mucous membrane IgA antibody level of chicken obviously. The DNA vaccine of the present invention has the advantages of safety, no interference on the monitoring of bird flu epidemic situation, capacity of overcoming the interference of maternal antibody, use convenience, etc.

The invention provides a meat duck online raising method, and relates to the field of commercial duck raising. The method includes the following steps that according to a place where a farm is located, ducklings adapting to the local growing environment are purchased; when the ducklings just enter the farm, adaptive raising for 1 to 3 days needs to be conducted; after adaptive raising, the maternal antibody conditions of the ducklings are detected, accordingly, immunization of an avian influenza vaccine and feed preparation are conducted, and primary immunization time is determined according to a maternal antibody fading rule; after being vaccinated, the ducklings are placed in a mesh raising house to be raised, suspended meshes are horizontally arranged in the raising house, and meat ducks are raised on the meshes until being slaughtered. The temperature and the humidity of the environment where the ducklings are located are adjusted according to a steam fumigation method, essential oil separated out from traditional Chinese medicine is contained in steam, stress of the ducklings to the new environment can be reduced, immunity of the ducklings is improved, and therefore the death rate of the ducklings is decreased when the ducklings enter the new environment; compound feed is mixed with water extract of traditional Chinese medicine auxiliary materials, so that the purposes that immunity of the ducks is improved and the slaughter period is shortened are achieved.

The invention discloses a nasal immune vaccine for a porcine epizootic diarrhea virus (PEDV) and a preparation method of the nasal immune vaccine. According to the preparation method, the nasal immune vaccine is prepared by mixing a vaccine concentrate for the porcine epizootic diarrhea virus, an adjuvant solution and a sodium azide solution at a specific ratio, wherein the adjuvant solution contains a TLR agonist, an agonist for an NOD sample receptor, carbomer and PVPK. Compared with an existing related vaccine, the nasal immune vaccine for the PEDV prepared by the method is high in titer and good in immune effect. The vaccine disclosed by the invention is subjected to vaccine immunization through a nasal mucosa tissue; meanwhile, mucosal immunization and system immunization of the organism are stimulated at the same time; a lot of sIgA is generated in sow milk; and a maternal antibody is transferred to piglets through milk so that the piglets obtain effective immune protection and the harms caused by the epidemic diarrhea of the piglets are prevented.

The invention discloses a feeding and management method for a female yak and a yak calf for producing traceable white yak calf meat. The steps include that a pregnant female yak is fed and managed in a mode of pasturing, a warm shed and supplementary feeding within three months before calving; after calving, healthy male yak calves with the birth weight larger than 12.5 kg are selected; the calves must suck beestings within 0.5-1 hour after birth and obtain maternal antibody as soon as possible, in the first 0-7 days, the beestings is mainly fed, in the day 7, paratyphoid immunization is conducted on the calves, and from the day 8 before the calves leave the shed, a feeding and management mode of full-breast-feeding and pasturing along with the female yak is practiced; simultaneously the female yak after giving birth to the calves is fed and managed in a mode of pasturing and supplementary feeding, after the calves are fed for 24-26 weeks, healthy bull calves with weight larger than 80 kilograms leave the shed and are butchered to produce the traceable white yak calf meat. The yak calves fed in a standard mode is tender in meat texture, and the meat is rich in amino acid, vitamin and the like required by human bodies and easy to digest and has Tibet plateau characteristics.

The present invention provides diagnostic methods for determining the risk of developing an autism spectrum disorder (ASD) in a fetus or child by detecting in a biological sample from the mother antibodies that bind to one or more biomarkers selected from the group consisting of lactate dehydrogenase (LDH), guanine deaminase (GDA), collapsin response mediator protein 1 (CRMP1), stress-induced phosphoprotein 1 (STIP1), alpha subunit of the barbed-end actin binding protein Cap Z (CAPZA2), Y Box Binding Protein 1 (YBX1), eukaryotic translation and elongation factor 1A1 (EEF1A1), microtubule-associated protein Tau (MAPT), dihydropyrimidinase-like protein 2 (DPYSL2), dynamin 1-like protein (DNM1L), radixin (RDX), moesin (MSN), and ezrin (EZR). The invention further provides methods of preventing or reducing the risk of a fetus or child developing an ASD by administering to the mother an agent that blocks the binding of maternal antibodies to the one or more fetal biomarkers listed above or by removing from the mother antibodies that bind to the one or more fetal biomarkers.

The invention provides a Muscovy duck parvovirus inactivation vaccine which comprises an antigen and a vaccine adjuvant, wherein the antigen is inactivated Muscovy duck parvovirus, and the collection number of the Muscovy duck parvovirus is CGMCC No.8504. The Muscovy duck parvovirus inactivation vaccine provided by the invention is prepared by the steps of screening a Muscovy duck parvovirus YBMDP strain with low toxicity and high immunogenicity; inoculating and collecting the virus liquid; performing ultrafiltration concentration and formaldehyde solution inactivation; adding an oil adjuvant and mixing and emulsifying to obtain the vaccine. The vaccine provided by the invention can improve the antibody level of Muscovy duck, guarantee the maternal antibody level of the filial generation and prevent the duckling parvovirus infection caused by the Muscovy duck parvovirus; the vaccine has the advantages of high efficiency and good safety.

The present invention relates to recombinant fowl pos virus vaccine constructing technology, and is especially recombinant fowl pos virus vaccine rFPV-1218AIH5/H9 and its construction process and use. Through setting the H5 subtype-containing AIV HA gene segment and H9 subtype-containing AIV HA gene segment separately in the downstream of respective promoter, back-to-back connecting serially, inserting into fowl pos virus expressing vector p12-18 containing FPV copying non-essential segment FPV12-18 and reporter gene LacZ to constitute transfer vector; transfecting wt-FPV-infecting chick embryo fibroblast with the transfer vector; and homogeneous recombination, virus vaccine with co-expressed H5 and H9 subtype AIV HA gene and free from interference of maternal antibody is obtained.

The invention discloses a blocking test paper for swine fever antibody. The test paper is composed of a support plate, an antigen pad, a gold standard pad, a detection membrane and an absorbent pad, wherein the antigen pad absorbs the detection antigen of swine fever virus, the gold standard pad absorbs the colloidal gold labeled anti-swine fever virus monoclonal antibody mAb1, the detection membrane contains "|" blots of a detection line T and a quality control line C, the detection line T is the blot of an anti-swine fever monoclonal antibody mAb2 or an anti-swine fever polyclonal antibody pAb1, and the quality control line C is the blot of an anti-mouse IgG antibody pAb2 or a staphylococcus aureus SPA. The test paper provided by the invention realizes the rapid detection of neutralizingantibody of swine fever virus, can realize real-time monitoring of the maternal antibody and immune antibody level of the swine fever as well as the immune evaluation of the vaccine immune effect, and is simple in operation and applicable for everyone, which can well meet the needs of different levels of personnel, is easy to promote and apply in a wide range, and has broad market prospects and large economic and social benefits.

The invention provides a biological product for treating gosling plague and a preparing method thereof. The technical scheme is based on the good controlling effect of an antigen-antibody compound on a virus, a combination scheme with VP3 protein as an antigen and an egg yolk antibody as an antibody is determined according to the characteristics of a gosling plague virus, and on this basis, the specific preparing methods of the VP3 protein and the egg yolk antibody are further designed. According to the technical scheme, on the basis of the original gosling-plague egg yolk antibody, the gosling-plague VP3 protein antigen is added, and a compound is prepared. The gosling-plague antigen-antibody compound can resist persistent infection caused by pathogenic microorganism, excess using of antibiotics is avoided, the interference of a maternal antibody is broken through, and an intense stress reaction caused by live vaccine is reduced; as the used antigen is not a complete virus antigen, but is the antigen prepared through the VP3 protein of the gosling plague, the danger that full viruses are dispersed outwards can be reduced, and the biological product is safer, more reliable and more effective.

The invention provides a Muscovy duck parvovirus and gosling plague bivalent vaccine. The antigens used by the vaccine is inactivated Muscovy duck parvoviruses and Muscovy duck-source gosling plague viruses, the preservation number of the Muscovy duck parvoviruses is CGMCC No. 8504, and the preservation number of the Muscovy duck-source gosling plague viruses is CCTCC No. V201620. A preparation method of the Muscovy duck parvovirus and gosling plague bivalent vaccine includes: the Muscovy duck parvovirus YBMDP strains and Muscovy duck-source gosling plague virus YBGPV-M strains which are high in virus content and good in immunogenicity are screened, infected embryos and allantoic fluid are collected after duck embryo inoculation, and oil emulsion adjuvant is added for emulsification and mixing to obtain the vaccine after homogenization, ultrafiltration and concentration, and formaldehyde solution inactivation. The prepared vaccine can immunize breeding Muscovy ducks and increase the level of two types of antibodies of the breeding Muscovy ducks at the same time, guarantee the offspring maternal antibody level of the breeding Muscovy ducks, and prevent the young Muscovy duck parvovirus diseases caused by the Muscovy duck parvoviruses and gosling plague virus infection caused by the Muscovy duck-source gosling plague viruses.

The present invention describes compositions and methods for priming protective immunity in the presence of pre-existing maternal antibody. In some embodiments, the invention contemplates simultaneously masking vaccines to avoid antibody neutralization while targeting those vaccines to specific cell types in order to elicit an enhanced immune response. In other embodiments, vectors that recruit and activate specific antigen-presenting cells may further enhance the efficacy of those immune responses.

The present invention relates to an infectious bursal disease live vaccine production method, which screens virulent strains with good immunogenicity, wider antigen spectrum and immune synergy from studies of characteristics of different infectious bursal disease virus such as immunogenicity, antigen spectrum, pathogenicity of bursa of Fabricius and capacity of breaking through maternal antibody, carries out development of the infectious bursal disease trivalent live vaccine, and develops a live vaccine--an infectious bursal disease trivalent live vaccine which has good immunogenicity, can break through higher level maternal antibody, has long immune duration more than 3 months, and has good protection to the various virulent strains.

The invention discloses a Newcastle disease virus strain rClone30-fliC and an application thereof in prevention and treatment of Newcastle disease. The Newcastle disease virus strain rClone30-fliC and a preparation method thereof are disclosed. The preparation method comprises a step of co-transfecting a constructed recombinant plasmid pBrClone30-fliC and corresponding auxiliary plasmids pBL-N, pBL-P and pBL-L to a BHK-21 cell which can stably express a T7 polymerase with rescue cultivation to obtain the Newcastle disease virus strain. In the invention, by means of introducing a molecular adjuvant fliC to a conventional Newcastle disease live vaccine genome, immunoreactions of an inoculated chicken is enhanced and an HI antibody is quickly generated beyond expectation so that an early-stage immune effect is achieved and an immune blanking period is reduced. Meanwhile, the Newcastle disease virus strain rClone30-fliC is free of interference of a maternal antibody and an immune protective effect is increased. The invention has an important value on prevention and treatment of the Newcastle disease.

The invention relates to a preparation method of a classical swine fever spleen-lymph-sourced compound living vaccine and belongs to the technical field of veterinary biological products. The preparation method of the classical swine fever spleen-lymph-sourced compound living vaccine comprises the following process steps: selecting a domestic rabbit to be inoculated; inoculating; measuring the temperature and observing; harvesting; preparing virus suspension and inspecting; carrying out mixed adsorption on the harvested full-suspension virus bulk and chicken anti-hog cholera virus egg yolk antibody; and adding freezing and drying protecting agent containing an immunopotentiator into antigen antibody compound obtained through adsorption, carrying out split charging, freezing, and carrying out vacuum drying, so that the classical swine fever spleen-lymph-sourced compound living vaccine is obtained. By adopting the preparation method of the classical swine fever spleen-lymph-sourced compound living vaccine, an antibody acquiring route is simple, animal welfare can be improved, manpower and material resources are saved, production cost is greatly reduced, humoral immunity of the living vaccine can be greatly improved, and high neutralizing antibodies can be produced; and the classical swine fever spleen-lymph-sourced compound living vaccine can be applied to piglet immunization, maternal antibody interference can be avoided, no interference is produced to other vaccines, especially a mycoplasma hyopneumoniae vaccine and the like, after the classical swine fever spleen-lymph-sourced compound living vaccine is applied to piglets, and strong mucosal immune response can be induced, so that protection rate is improved.

The invention discloses a DHAV (Duck Hepatitis A Virus) III type complex live vaccine and a preparation method thereof. The method firstly discloses the DHAV III type complex live vaccine, which comprises antigen-antibody complex and pharmaceutically acceptable freeze-drying protective agents, wherein the antigen-antibody complex is prepared from DHAV III type chick embryo weakening strain JS57 virus liquid and duck anti-DHAV III type egg yolk antibodies. The invention further discloses a preparation method of the DHAV III type complex live vaccine. The preparation method comprises the following steps of mixing the freeze-drying protective agents with the antigen-antibody complex prepared from the DHAV III type chick embryo weakening strain JS57 virus liquid and the duck anti-DHAV III type egg yolk antibodies; performing freeze vacuum drying; and obtaining the DHAV III type complex live vaccine. The preparation method provided by the invention has the advantages that the antibody obtaining path is simple; the production cost is low; the prepared DHAV III type complex live vaccine can break through the maternal antibody interference to generate high neutralizing antibody valence; and the production rate on ducklings is improved.

The invention aims to provide a muscovy duck parvovirus subunit vaccine. The muscovy duck parvovirus subunit vaccine comprises an antigen and a vaccine adjuvant, wherein the used antigen is muscovy duck parvovirus VP protein; and the amino acid sequence of the muscovy duck parvovirus VP protein is SEQ ID NO: 1. After muscovy ducks are inoculated with the vaccine prepared by the invention, the antibody level of the muscovy ducks can be improved, the maternal antibody level of filial generation is guaranteed, and young muscovy duck goose parvovirus infection caused by muscovy duck source goose parvovirus is prevented. If young muscovy ducks at the age of one day are inoculated with the vaccine, the young muscovy duck goose parvovirus infection caused by muscovy duck source goose parvovirus can be prevented effectively.

The invention belongs to the technical field of application of reverse genetics and gene replacement, and particularly relates to a chimeric Newcastle disease virus vaccine vector candidate strain capable of overcoming the influence of a maternal antibody of a Newcastle disease and a construction method of the chimeric Newcastle disease virus vaccine vector candidate strain. The candidate strain is avian paramyxovirus type-1 AI4-T4FHN, and the preservation number is CGMCC No:12987. An established reverse genetics manipulation platform for a Newcastle disease virus gene type-VII attenuated virus strain AI4 is utilized to replace the corresponding part of a genome of the strain AI4 through the sequence of an extracellular region of envelope proteins F and HN of an avian paramyxovirus type-2, and the recombinant virus AI4-T4FHN is obtained through saving. The cross reaction capacity of the avian paramyxovirus type-2 and the Newcastle disease virus are very weak, and the avian paramyxovirus type-2 is not pathogenic for a chicken. The chimeric virus has a high reproductive capacity similar to that of a female parent virus, and meanwhile, the chimeric virus is effectively replicated in the chicken body with the maternal antibody of the Newcastle disease at high level, and is a novel vaccine carrier.

The invention discloses a detection kit for chicken infectious bronchitis indirect ELISA antibody, belonging to the field of biotechnology. According to the invention, genetically engineered bacterium capable of steadily expressing partial nucleoprotein of chicken infectious bronchitis virus is utilized for inducible expression of recombined N160 protein which is subjected to affinity chromatographic purification, and the purified recombined N160 protein is taken as a coating antigen, so as to establish a simple and convenient and specific indirect ELISA method. The invention further provides a specific, sensitive, quick and convenient-to-operate kit for detecting the antibody of the chicken infectious bronchitis virus, which can be used for quickly diagnosing whether the chicken flocks are infected by the chicken infectious bronchitis virus and monitoring the immune chicken serum antibody level and the chicken maternal antibody level in actual production, so as to evaluate the degree of risk that the chicken flocks are infected by the infectious bronchitis virus and provide reference for the formulation of an infectious bronchitis immune procedure.

The invention provides a vaccine composition, comprising an immune amount of muscovy duck Parvovirus antigen and an immune amount of muscovy duck parvovirus antibody. The vaccine composition can be applied to immunization of young muscovy duck, also can be directly applied to immunization of muscovy duck embryo; the immunization effect is not affected by maternal antibody, and quickly produces immunity, and ideal protection can be produced of the in the second day after immunization; attacked by strong virus, the immune ducks 5 / 5 have no morbidity, and control ducks 5 / 5 are dead.

The invention relates to a chimeric Newcastle disease virus vector H7 (avian influenza) live vaccine candidate strain capable of overcoming an effect of a Newcastle disease virus maternal antibody of a chick and a construction method thereof. The preservation number of the Newcastle disease vaccine candidate strain is CGMCC No.13798. The construction method includes: making use of a reverse genetic manipulation platform of a chimeric Newcastle disease virus rAI4-TFHN which is capable of being replicated in the existence of a Newcastle disease antibody, inserting an HA (hemagglutinin) sequence of a subtype H7N9 (avian influenza) virus strain into a full-length transcription vector of an AI4-T4FHN strain genome so as to obtain a full-length cDNA (complementary deoxyribonucleic acid) clone pNDV/rAI4-T4FHN-H7 of a recombinant Newcastle disease virus genome containing the subtype HA gene of the H7N9 (avian influenza) virus. The recombinant virus AI4-T4FHN-H7 obtained through transfection is high in propagation titer in chick embryos, still capable of expressing HA protein stably after continuous passage and applicable to large-scale production of vaccine and can be used for manufacturing the vaccine.